Download Report

Global Next Generation Antibody Therapeutics Market :
Forecast 2016 - 2022
Persistence Market Research
Global Next-generation Antibody
Therapeutics Market Expected to Progress
US$ 6,761.1 Million by 2022 - Persistence
Market Research
Persistence Market Research
1
Global Next Generation Antibody Therapeutics Market :
Forecast 2016 - 2022
Persistence Market Research Released New Market Report “Global Next Generation Antibody
Therapeutics Market : Forecast 2016 - 2022”, the global next-generation antibody therapeutics market
is project to be valued at US$ 2,250.0 Mn by the end of 2015 and is expected to expand at a CAGR of
13.0% from 2015 to 2022, to account for US$ 6,761.1 Mn by 2022.
Next-generation antibody therapeutics refers to improved antibody therapeutics with enhanced efficiency,
greater safety, and improved delivery. Advancements in monoclonal antibody technologies have led to the
development of next-generation therapeutic antibodies with reduced functional size, greater bifunctional
properties, and low immunogenicity. Next-generation antibody-based therapeutics enhances existing
properties of therapeutic antibodies for the treatment of various medical conditions such as cancer,
infectious diseases, and autoimmune diseases.
Globally, the next-generation antibody therapeutics market is witnessing significant growth due to
technological advancements in antibody therapeutics and increasing the prevalence of chronic diseases.
In addition, rising healthcare expenditure and growing R & D activities are driving the growth of the nextgeneration antibody therapeutics market. However, stringent regulatory requirements and long approval
time for new drug restrains the growth of the market. Similarly, high costs of next-generation antibody
therapeutics is a major concern for the market.
Interested in report: Please follow the below links to meet your requirements; Request for the
Report Sample: http://www.persistencemarketresearch.com/samples/3713
North America is the largest market for next-generation antibody therapeutics. This is mainly due to
increasing prevalence of chronic diseases and increasing healthcare spending in the region. The North
America next-generation antibody therapeutics market is projected to be valued at US$ 1,104.4 Mn by the
end of 2015 and is expected to account for US$ 3,691.8 Mn by 2022 at a CAGR of 14.5%. On the basis
of technology, biosimilar antibody products are the fastest growing segment. On the basis of therapeutic
application, oncology is the largest segment in next-generation antibody therapeutics market.
Persistence Market Research
2
Global Next Generation Antibody Therapeutics Market :
Forecast 2016 - 2022
Roche, Seattle Genetics, Takeda, Dyax Corp., and Immunogen are some of the leading players in the
global market of next-generation antibody therapeutics. Some of the other major players in nextgeneration antibody therapeutics market are Amgen, Inc., Biogen, Kyowa Hakko Kirin Co., Ltd.,
AstraZeneca, Pfizer, Inc., and Xencor, Inc.
Request TOC (table of content), Figures and Tables of the Report:
http://www.persistencemarketresearch.com/toc/3713
The next-generation antibody therapeutics market is segmented as follows:
For more info: http://www.persistencemarketresearch.com/contact-us.asp
By Technology
•
Antibody-Drug Conjugates (ADCs)
•
Bispecific Antibodies (BsAbs)
•
Fc Engineered Antibodies
•
Antibody Fragments and Antibody-like Proteins
•
Biosimilar Antibody Products
By Therapeutic Application
•
Oncology
•
Autoimmune/Inflammatory Diseases
By Geography
•
North America
•
Europe
•
Asia
•
Rest of the World (RoW)
Persistence Market Research
3
Global Next Generation Antibody Therapeutics Market :
Forecast 2016 - 2022
Market History:
Success of monoclonal antibodies has encouraged researchers to discover and develop next-generation
of antibodies. Next-generation antibody therapeutics are improved antibody therapeutics that are highly
efficient, offer greater safety, and are easier to deliver. Globally, the next-generation antibody therapeutics
market is witnessing significant growth due to growing R&D activities, increasing prevalence of chronic
diseases, and technological advancements in antibody therapeutics. In addition, increasing healthcare
expenditure is also driving growth of the global next-generation antibody therapeutics market. However,
factors such as high costs of next generation antibody therapeutics, stringent regulatory requirements,
and long approval time are restraining growth of the market. The global next-generation antibody
therapeutics market is projected to be valued at US$ 2,250.0 Mn by the end of 2015. It is likely to grow at
a CAGR of 13.0% to account for US$ 6,761.1 Mn by 2022.
North America is the largest market for next-generation antibody therapeutics. In terms of technology,
antibody-drug conjugates are the largest segment in the global next-generation antibody therapeutics
market. On the basis of therapeutic application, oncology dominates the next-generation antibody
therapeutics market. The North America next-generation antibody therapeutics market is anticipated to be
valued at US$ 1,104.4 Mn by the end of 2015 and is expected to account for US$ 3,691.8 Mn by 2022 at
a CAGR of 14.5%. One of the latest trends in the next-generation antibody therapeutics market is the
increasing use of ADC technology.
Various biotechnology and biopharmaceutical companies are actively involved in development and
manufacture of next-generation antibodies. Some of the major players in the market are F. Hoffmann-La
Roche Ltd., Dyax Corp., Kyowa Hakko Kirin Co., Ltd., Seattle Genetics, Inc. ImmunoGen, Inc., Amgen,
Inc., Biogen, Bayer AG, and Xencor, Inc.
Persistence Market Research
4
Global Next Generation Antibody Therapeutics Market :
Forecast 2016 - 2022
Persistence Market Research
5
Global Next Generation Antibody Therapeutics Market :
Forecast 2016 - 2022
Table of Content
Chapter 1 Preface 10
1.1 Report Description 10
1.2 Research Methodology 11
1.3 Assumptions 11
Chapter 2 Market Synopsis 12
Chapter 3 Porter’s Five Forces Analysis 14
3.1 Bargaining Power of Suppliers 14
3.2 Bargaining Power of Buyers 14
3.3 Threat of New Entrants 14
3.4 Threat of Substitutes 14
3.5 Intensity of Rivalry 14
Chapter 4 Industry Overview 15
4.1 Market Definition 15
4.2 Market Drivers 17
4.2.1 Growing R&D activities 17
4.2.2 Increasing prevalence of chronic diseases 18
4.2.3 Technological advancements in antibody therapeutics 18
4.2.4 Increasing healthcare expenditure 19
4.3 Impact Analysis of Market Drivers 20
4.4 Restraints 22
4.4.1 Stringent regulatory requirements and long approval times for new drugs 22
4.4.2 High costs of next-generation antibody therapeutics 23
4.5 Impact Analysis of Market Restraints 24
4.6 Market Trends 24
4.6.1 Increasing usage of antibody-drug conjugates (ADC) technology is gaining popularity in nextgeneration antibody therapeutics market 24
4.6.2 Rising number of collaborations for development of next-generation antibody therapeutics 25
Persistence Market Research
6
Global Next Generation Antibody Therapeutics Market :
Forecast 2016 - 2022
Chapter 5 Major Next-generation Antibody Therapeutics Pipeline Drugs 28
Chapter 6 Global Market Size and Forecast 33
6.1 On the Basis of Geography 33
6.2 On the Basis of Therapeutic Area 34
6.3 On the Basis of Technology 36
Chapter 7 Market Size and Forecast by Therapeutic Area 38
7.1 Oncology 38
7.2 Autoimmune/Inflammatory 40
Chapter 8 Market Size and Forecast by Technology 42
8.1 Antibody-drug conjugates (ADCs) 42
8.2 Bispecific antibodies 44
8.3 Fc engineered antibodies 46
8.4 Antibody fragments and antibody-like proteins 48
8.5 Biosimilar antibody products 51
Chapter 9 Market Size and Forecast by Geography 53
9.1 North America 53
9.2 Europe 56
9.3 Asia 61
9.4 Rest of the World 64
Chapter 10 Competitive Scenario 65
10.1 Competitive Benchmarking 65
10.2 Company Share Analysis 67
Chapter 11 Company Profiles 69
11.1 F. Hoffmann-La Roche Ltd 69
11.1.1 Company Overview 69
11.1.2 Products and services 70
11.1.3 Financial performance 71
11.1.4 Key Developments 71
11.2 Kyowa Hakko Kirin Co., Ltd. 73
Persistence Market Research
7
Global Next Generation Antibody Therapeutics Market :
Forecast 2016 - 2022
11.2.1 Company Overview 73
11.2.2 Products and Services 74
11.2.3 Financial performance 75
11.2.4 Key Developments 75
11.3 Seattle Genetics, Inc. 77
11.3.1 Company Overview 77
11.3.2 Products and Services 77
11.3.3 Financial performance 78
11.3.4 Key Developments 78
11.4 ImmunoGen, Inc. 80
11.4.1 Company Overview 80
11.4.2 Products and Services 80
11.4.3 Financial performance 81
11.4.4 Key Developments 81
11.5 Bristol-Myers Squibb Company 83
11.5.1 Company Overview 83
11.5.2 Products and Services 83
11.5.3 Financial performance 84
11.5.4 Key Developments 84
11.6 Pfizer, Inc. 87
11.6.1 Company Overview 87
11.6.2 Products and Services 87
11.6.3 Financial performance 88
11.6.4 Key Developments 88
11.7 Amgen, Inc. 90
11.7.1 Company Overview 90
11.7.2 Products and Services 90
11.7.3 Financial performance 91
11.7.4 Key Developments 91
11.8 Biogen 93
11.8.1 Company Overview 93
11.8.2 Products and Services 93
11.8.3 Financial performance 94
11.8.4 Key Developments 94
11.9 Bayer AG 95
Persistence Market Research
8
Global Next Generation Antibody Therapeutics Market :
Forecast 2016 - 2022
11.9.1 Company Overview 95
11.9.2 Products and Services 95
11.9.3 Financial performance 96
11.9.4 Key Developments 96
11.10 Xencor, Inc. 97
11.10.1 Company Overview 97
11.10.2 Products and Services 97
11.10.3 Financial performance 98
11.10.4 Key Developments 98
11.11 Takeda Pharmaceuticals Company Limited 99
11.11.1 Company Overview 99
11.11.2 Products and services 99
11.11.3 Financial performance 100
11.11.4 Key Developments 101
11.12 AstraZeneca 102
11.12.1 Company Overview 102
11.12.2 Products and Services 102
11.12.3 Financial performance 103
11.12.4 Key Developments 103
11.13 Dyax Corp. 105
11.13.1 Company Overview 105
11.13.2 Products and Services 105
11.13.3 Financial performance 106
11.13.4 Key Developments 106
Persistence Market Research
9
Global Next Generation Antibody Therapeutics Market :
Forecast 2016 - 2022
List of Tables
TABLE 1 Market snapshot: Next-generation antibody therapeutics market, 2015 and 2022 12
TABLE 1 Drivers for next-generation antibody therapeutics market: Impact analysis 20
TABLE 2 Estimated average timelines for clinical trial approval in various countries 22
TABLE 3 Restraints for next-generation antibody therapeutics market: Impact analysis 24
TABLE 4 Major collaborations in next-generation antibody therapeutics market (2012- April 2015) 26
TABLE 6 Global next-generation antibody therapeutics market size, by region, 2010 – 2013 (US$ Mn) 33
TABLE 7 Global next-generation antibody therapeutics market size, by region, 2014 – 2020 (US$ Mn) 34
TABLE 8 Global next-generation antibody therapeutics market size, by therapeutic area, 2010 – 2013
(US$ Mn) 35
TABLE 9 Global next-generation antibody therapeutics market size, by application, 2014 – 2020 (US$
Mn) 35
TABLE 10 Global next-generation antibody therapeutics market size, by technology, 2010 – 2013 (US$
Mn) 37
TABLE 11 Global next-generation antibody therapeutics market size, by technology, 2014 – 2020 (US$
Mn) 37
TABLE 12 Global oncology next-generation Ab therapeutics market size, by region, 2010 – 2013 (US$
Mn) 39
TABLE 13 Global oncology next-generation Ab therapeutics market size, by region, 2014 – 2020 (US$
Mn) 39
TABLE 14 Global autoimmune/inflammatory next-generation Ab therapeutics market size, by region, 2010
– 2013 (US$ Mn) 40
TABLE 15 Global autoimmune/inflammatory next-generation Ab therapeutics market size, by region, 2014
– 2020 (US$ Mn) 41
TABLE 16 Global ADCs market size, by region, 2010 – 2013 (US$ Mn) 43
TABLE 17 Global ADCs market size, by region, 2014 – 2020 (US$ Mn) 43
TABLE 18 Global BsAbs market size, by region, 2010 – 2013 (US$ Mn) 44
TABLE 19 Global BsAbs market size, by region, 2014 – 2020 (US$ Mn) 45
TABLE 20 Global Fc engineered antibodies market size, by region, 2010 – 2013 (US$ Mn) 47
TABLE 21 Global Fc engineered antibodies market size, by region, 2014 – 2020 (US$ Mn) 47
TABLE 22 Global antibody fragments and antibody-like proteins market size, by region, 2010 – 2013
(US$ Mn) 49
TABLE 23 Global antibody fragments and antibody-like proteins market size, by region, 2014 – 2020
(US$ Mn) 49
Persistence Market Research
10
Global Next Generation Antibody Therapeutics Market :
Forecast 2016 - 2022
TABLE 24 Global biosimilar antibody products market size, by region, 2010 – 2013 (US$ Mn) 52
TABLE 25 Global biosimilar antibody products market size, by region, 2014 – 2020 (US$ Mn) 52
TABLE 26 North America next-generation antibody therapeutics market size, by country, 2010 – 2013
(US$ Mn) 54
TABLE 27 North America next-generation antibody therapeutics market size, by country, 2014 – 2020
(US$ Mn) 54
TABLE 28 Europe next-generation antibody therapeutics market size, by country, 2010 – 2013 (US$ Mn)
59
TABLE 29 Europe next-generation antibody therapeutics market size, by country, 2014 – 2020 (US$ Mn)
60
TABLE 30 Asia next-generation antibody therapeutics market size, by country, 2010 – 2013 (US$ Mn) 62
TABLE 31 Asia next-generation antibody therapeutics market size, by country, 2014 – 2020 (US$ Mn) 63
TABLE 32 Major product categories of Roche 70
TABLE 33 Major product segments of Kyowa Hakko Kirin Co., Ltd. 74
TABLE 34 Major product categories of Seattle Genetics, Inc. 77
TABLE 35 Product category of ImmunoGen, Inc. 80
TABLE 36 Major product segments of Bristol-Myers Squibb Company 83
TABLE 37 Major product segments of Pfizer, Inc. 87
TABLE 38 Major product categories of Amgen 90
TABLE 39 Major categories of therapies of Biogen 93
TABLE 40 Major product categories of Bayer AG 95
TABLE 41 Product category of Xencor 97
TABLE 42 Major product categories of Takeda 100
TABLE 43 Major product categories of AstraZeneca 102
TABLE 44 Product category of Dyax Corp. 105
Persistence Market Research
11
Global Next Generation Antibody Therapeutics Market :
Forecast 2016 - 2022
List of Figures
FIG. 1 Next-generation antibody therapeutics market: Porter’s five force analysis 14
FIG. 2 Health expenditure as total percentage of GDP, 2002 and 2012 20
FIG. 3 Global next-generation antibody therapeutics market share, by region, by value, 2013 33
FIG. 4 Global next-generation antibody therapeutics market share, by therapeutic area, by value, 2013 34
FIG. 5 Global next-generation antibody therapeutics market share, by technology, by value, 2013 36
FIG. 6 Global oncology next-generation Ab therapeutics market share, by region, by value, 2013 38
FIG. 7 Global autoimmune/inflammatory next-generation Ab therapeutics market share, by region, by
value, 2013 40
FIG. 8 Global ADCs market share, by region, by value, 2013 42
FIG. 9 Global BsAbs market share, by region, by value, 2013 44
FIG. 10 Global Fc engineered antibodies market share, by region, by value, 2013 46
FIG. 11 Global antibody fragments and antibody-like proteins market share, by region, by value, 2013 48
FIG. 12 Global biosimilar antibody products market share, by region, by value, 2013 51
FIG. 13 North America next-generation antibody therapeutics market share, by country, by value, 2013 54
FIG. 16 Europe next-generation antibody therapeutics market share, by country, by value, 2013 59
FIG. 17 Asia next-generation antibody therapeutics market share, by country, by value, 2013 62
FIG. 18 Competitive benchmarking of next-generation antibody therapeutics 65
FIG. 19 Global next-generation antibody therapeutics market, by company 2014 (% share) 67
FIG. 20 Sales and net income of Roche, 2012 – 2014 (US$ Mn) 71
FIG. 21 Net sales and net income of Kyowa Hakko Kirin Co., Ltd., 2012 – 2014 (US$ Mn) 75
FIG. 22 Total revenue and net loss of Seattle Genetics, Inc., 2012 – 2014 (US$ Mn) 78
FIG. 23 Total revenue and net loss of ImmunoGen, Inc., 2012 – 2014 (US$ Mn) 81
FIG. 24 Total revenue and net earnings of Bristol-Myers Squibb Company, 2012 – 2014 (US$ Mn) 84
FIG. 25 Revenue and net income of Pfizer, Inc., 2012 – 2014 (US$ Mn) 88
FIG. 26 Revenue and net income of Amgen, 2012 – 2014 (US$ Mn) 91
FIG. 27 Total revenue and net income of Biogen, 2012 – 2014 (US$ Mn) 94
FIG. 28 Net sales and net income of Bayer AG, 2012 – 2014 (US$ Mn) 96
FIG. 29 Revenues and net loss of Xencor, 2012 – 2014 (US$ Mn) 98
FIG. 30 Revenue and net profit of Takeda, 2012 – 2014 (US$ Mn) 100
FIG. 31 Revenue and profit of AstraZeneca, 2012 – 2014 (US$ Mn) 103
FIG. 32 Total revenue and net loss of Dyax Corp., 2012 – 2014 (US$ Mn) 106
Persistence Market Research
12
Global Next Generation Antibody Therapeutics Market :
Forecast 2016 - 2022
About Us:
Persistence Market Research (PMR) is a full-service market intelligence firm specializing in syndicated
research, custom research, and consulting services. PMR boasts market research expertise across the
Healthcare, Chemicals and Materials, Technology and Media, Energy and Mining, Food and Beverages,
Semiconductor and Electronics, Consumer Goods, and Shipping and Transportation industries. The
company draws from its multi-disciplinary capabilities and high-pedigree team of analysts to share data
that precisely corresponds to clients’ business needs.
PMR stands committed to bringing more accuracy and speed to clients’ business decisions. From readyto-purchase market research reports to customized research solutions, PMR’s engagement models are
highly flexible without compromising on its deep-seated research values.
Contact Us:
Persistence Market Research
305 Broadway
7th Floor, New York City,
NY 10007, United States,
USA - Canada Toll Free: 800-961-0353
Email: [email protected]
Web: http://www.persistencemarketresearch.com
Persistence Market Research
13